Literature DB >> 24165252

Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival.

Shreya Shetty1, Bala Natarajan, Peter Thomas, Venkatesh Govindarajan, Poonam Sharma, Brian Loggie.   

Abstract

The nomenclature and classification of pseudomyxoma peritonei (PMP) is confusing and controversial. Numerous classification systems have been proposed, none of which are easily reproducible or a useful guide for treatment. Patients with PMP of appendiceal origin were identified from our institution's database. Kaplan-Meier analyses were performed based on a proposed new PMP classification, a three-tiered grading system designated PMP1, PMP2, and PMP3. These results were compared with the established schemes by Ronnett and Bradley et al. There were 211 patients included in the analysis with a mean age of 51 ± 12 years at diagnosis. For PMP1, 86 patients (40.8%) included cases with abundant extracellular mucin and columnar nonstratified epithelium without dysplasia or atypia. For PMP3, 50 patients (23.7%) consisted of PMP with any percentage of signet ring cells (SRCs), For PMP2, 75 patients (35.5%) included all other patients. The mean age (± standard deviation) for PMP 1, 2, and 3 were 51 ± 12, 51 ± 12, and 51 ± 10 years, respectively (P = 0.90). The three groups had similar sex distribution (P = 0.24) and resection status (P = 0.47). Kaplan-Meier analyses showed median survivals of 120, 88, and 40 months and 5-year survival rates of 85.7, 63.05, and 32.2 per cent (P < 0.0001) for PMP 1, 2, and 3, respectively. Three distinct categories, PMP1, 2, and 3, were identified, which provide better stratification in terms of overall survival and represent differences in tumor biology that may impact treatment recommendations.

Entities:  

Mesh:

Year:  2013        PMID: 24165252

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  14 in total

1.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.

Authors:  Ayman Zaki Azzam; Zyad Adil Alyahya; Ahmed Abbas Al Wusaibie; Tarek Mahmoud Amin
Journal:  Indian J Gastroenterol       Date:  2017-11-29

Review 2.  New insights in the pathology of peritoneal surface malignancy.

Authors:  Norman John Carr
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  Enhanced computed tomography imaging features predict tumor grade in pseudomyxoma peritonei.

Authors:  Pengtao Sun; Xinbao Li; Lingling Wang; Rengui Wang; Xuechao Du
Journal:  Quant Imaging Med Surg       Date:  2022-04

Review 4.  Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei.

Authors:  Veena Ramaswamy
Journal:  Indian J Surg Oncol       Date:  2016-03-19

5.  Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei and Appendix Tumours.

Authors:  Joshua Lansom; Nayef Alzahrani; Winston Liauw; David L Morris
Journal:  Indian J Surg Oncol       Date:  2015-10-24

6.  Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.

Authors:  Edward A Levine; John H Stewart; Perry Shen; Gregory B Russell; Brian L Loggie; Konstantinos I Votanopoulos
Journal:  J Am Coll Surg       Date:  2013-12-21       Impact factor: 6.113

Review 7.  The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies.

Authors:  Mackenzie C Morris; Jordan M Cloyd; John Hays; Sameer H Patel
Journal:  J Gastrointest Surg       Date:  2020-08-17       Impact factor: 3.452

Review 8.  Essentials for Pathological Evaluation of Peritoneal Surface Malignancies and Synoptic Reporting of Cytoreductive Surgery Specimens-A review and evidence-based guide.

Authors:  Aditi Bhatt; Suniti Mishra; Loma Parikh; Sandeep Sheth; Imran Gorur
Journal:  Indian J Surg Oncol       Date:  2019-03-19

Review 9.  Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.

Authors:  Afshin Amini; Samar Masoumi-Moghaddam; Anahid Ehteda; David Lawson Morris
Journal:  Orphanet J Rare Dis       Date:  2014-05-05       Impact factor: 4.123

10.  Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment.

Authors:  Murali R Kuracha; Peter Thomas; Brian W Loggie; Venkatesh Govindarajan
Journal:  Cancer Med       Date:  2016-02-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.